Universe Pharmaceuticals Inc (UPC) FinancialsUPCUniverse Pharmaceuticals Inc

Universe Pharmaceuticals Inc (UPC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sales of TCMD products, accounting for 50.8% of total sales, equivalent to $9.37M. Another important revenue stream is Sales of third-party products. Understanding this composition is critical for investors evaluating how UPC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Universe Pharmaceuticals Inc maintains a gross margin of 36.99%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.60%, while the net margin is -17.21%. These profitability ratios, combined with a Return on Equity (ROE) of -3.50%, provide a clear picture of how effectively UPC converts its operational activities into shareholder value.

In the context of the broader market, UPC competes directly with industry leaders such as ALZN and SNGX. With a market capitalization of $7.08M, it holds a significant position in the sector. When comparing efficiency, UPC's gross margin of 36.99% stands against ALZN's N/A and SNGX's N/A. Such benchmarking helps identify whether Universe Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company reported a revenue of $9.03 million with a net loss of $1.55 million for the six months ending March 31, 2026, which is an improvement from a $3.28 million loss last year, but still indicates ongoing financial struggles.